Cyclosporine Use During Pregnancy: Safety, Dosing, Monitoring, and Disease‑Specific Guidance

Safety & Teratogenicity

• Cyclosporine is not teratogenic; extensive human data show no specific pattern of birth defects and malformation rates comparable to the general population【1】【2】【3】 (moderate‑quality evidence).
• The American College of Rheumatology 2020 guidelines classify cyclosporine as compatible with pregnancy and recommend its continuation with blood‑pressure monitoring【2】 (conditional recommendation).
• The 2016 consensus on acute severe ulcerative colitis states that cyclosporine can be used during pregnancy without an increase in fetal malformations【3】 (conditional recommendation).

Pregnancy‑Related Complications

• Prematurity is more common in cyclosporine‑exposed pregnancies, with preterm delivery rates >40 % in transplant cohorts and a pooled prevalence of 56.3 % (OR 1.52, not statistically significant)【1】 (moderate‑quality evidence).
• Lower birth weight has been documented in both human studies and animal models of cyclosporine exposure【1】 (moderate‑quality evidence).
• Maternal hypertension and pre‑eclampsia occur frequently, although they may be confounded by the underlying disease【1】【3】 (moderate‑quality evidence).
• No evidence indicates that maternal cyclosporine exposure causes renal damage in offspring, despite animal data showing reduced nephron counts【1】 (moderate‑quality evidence).

Dosing Recommendations

• Maintain the standard dose of 2.5–5.0 mg/kg/day divided into two doses throughout pregnancy【1】 (expert consensus).
• Reduce the dose by 0.25–1.0 mg/kg if hypertension or declining renal function develops【1】 (expert consensus).

Monitoring Requirements

• Blood‑pressure monitoring is the primary surveillance measure; check every 2 weeks during the first trimester, then monthly thereafter【2】【1】 (conditional recommendation).
• Renal function: measure BUN and creatinine every 2 weeks for the first 3 months, then monthly【1】 (expert consensus).
• Laboratory panel: obtain a CBC, liver‑function tests, lipid profile, magnesium, uric acid, and potassium monthly【1】 (expert consensus).
• Perform pregnancy testing when clinically indicated【1】 (expert consensus).

Disease‑Specific Recommendations

Inflammatory Bowel Disease

• For acute severe ulcerative colitis, cyclosporine may be used at any stage of pregnancy without altering the management algorithm【3】 (conditional recommendation).
• Active IBD poses greater risks to the fetus (preterm birth, stillbirth, neonatal death) than cyclosporine exposure【3】 (moderate‑quality evidence).

Rheumatic Diseases

• The American College of Rheumatology advises conditional continuation of cyclosporine during pregnancy, coupled with blood‑pressure monitoring【2】 (conditional recommendation).

Dermatologic Conditions / Transplant Patients

• The American Academy of Dermatology notes lower birth weight and shorter gestation in transplant recipients but confirms cyclosporine is non‑teratogenic【1】 (moderate‑quality evidence).

Breastfeeding Considerations

• A decision must be made to either discontinue breastfeeding or stop cyclosporine, as the drug passes into breast milk and contains ethanol that can be absorbed by the infant【1】【3】 (expert consensus).
• A case report described therapeutic cyclosporine concentrations in a breast‑fed infant without observable adverse effects【3】 (low‑level case evidence).

Clinical Pitfalls & Drug Interactions

• Avoid nephrotoxic drug combinations (e.g., aminoglycosides, NSAIDs) that increase cyclosporine‑related nephrotoxicity【1】 (expert consensus).
• Monitor for hyper‑kalemia when potassium‑sparing diuretics are co‑prescribed, as they can potentiate dangerous potassium elevation【1】 (expert consensus).
• Cyclosporine is metabolised by CYP3A4; be aware of interactions with statins, calcium‑channel blockers, and warfarin【1】 (expert consensus).

Evidence Quality Summary

• The most robust data derive from transplant populations with extensive longitudinal follow‑up, providing high‑quality observational evidence of safety【1】.
• Evidence in autoimmune diseases (rheumatic and IBD) is more limited but consistently reassuring, representing moderate‑quality evidence【2】【3】.

Cyclosporine Safety During Pregnancy

Safety Profile in Pregnancy

• Cyclosporine does not appear to be teratogenic based on extensive experience in transplant recipients and patients with autoimmune conditions 4, 5
• The American Academy of Dermatology classifies cyclosporine as FDA pregnancy category C, meaning it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus 6
• No specific birth defects or pattern of malformations have been linked to cyclosporine exposure during pregnancy 6
• There is no evidence that maternal cyclosporine use during pregnancy causes renal damage in exposed children, despite concerns raised in animal studies 6, 7, 8

Potential Pregnancy Complications

• Increased rates of prematurity have been observed in human studies of women taking cyclosporine during pregnancy 7, 9
• Lower birth weight and increased prenatal and postnatal mortality have been reported in animal studies 7
• Hypertension and preeclampsia may be associated with cyclosporine use during pregnancy, although this may be confounded by underlying maternal conditions 10

Use in Specific Conditions

• The European League Against Rheumatism considers cyclosporine compatible with pregnancy and includes it among medications that can be continued during pregnancy 11
• For inflammatory bowel disease, cyclosporine can be used during pregnancy when needed for severe disease, with no significant increase in fetal malformations 10
• For dermatologic conditions like psoriasis, cyclosporine has been used effectively during pregnancy, including for generalized pustular psoriasis 4, 5

Monitoring and Management During Pregnancy

• Women should be informed of the risks associated with cyclosporine during pregnancy before starting therapy 7, 9
• Regular monitoring of blood pressure is essential, as cyclosporine-induced hypertension occurs in approximately 20% of patients 12
• Early morning resting blood pressure is a sensitive indicator of early nephrotoxicity and should be monitored regularly 9, 12
• If hypertension develops during pregnancy, consider dose reduction of cyclosporine and use calcium channel blockers as the preferred antihypertensive agents 9, 12

Breastfeeding Considerations

• Cyclosporine passes into breast milk and contains ethanol that will be orally absorbed by the nursing infant 7, 9
• A decision should be made whether to discontinue breastfeeding or discontinue cyclosporine based on the importance of the drug to the mother 7, 9

Important Caveats

• The decision to use cyclosporine during pregnancy should involve careful consideration of the risk-benefit ratio 4, 11
• Discontinuation of necessary immunosuppression during pregnancy may lead to disease flares or transplant rejection, which could pose greater risks to both mother and fetus than continuing treatment 11, 13